2. Search Result
Search Result
Results for "

gastritis

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Inhibitory Antibodies

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-75424A
    2-(Trifluoromethyl)cinnamic acid

    		Proton Pump Inflammation/Immunology
    2-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative that inhibits the proton pump (H +/K +-ATPase), thereby reducing gastric acid secretion. 2-(Trifluoromethyl)cinnamic acid also improves delayed gastric emptying and can be used in research on gastric diseases such as acute gastritis and gastric ulcers .
    2-(Trifluoromethyl)cinnamic acid
  • HY-B0758
    Troxipide

    		Others Inflammation/Immunology
    Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties .
    Troxipide
  • HY-N0366
    Sennoside B
    3 Publications Verification

    		 PDGFR Inflammation/Immunology
    Sennoside B is a potent and orally active platelet-derived growth factor (PDGF) inhibitor. Sennoside B inhibits cell proliferation and the expression of phosphorylation of PDGFR-β, STAT-5, AKT and ERK induced by PDGF-BB. Sennoside B shows gastroprotective activities. Sennoside B has the potential for the research of gastritis .
    Sennoside B
  • HY-P99371
    Lirentelimab

    AK002; Antolimab

    		 Apoptosis Inflammation/Immunology
    Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
    Lirentelimab
  • HY-B0360
    Rebamipide
    4 Publications Verification

    OPC12759; Proamipide

    		 COX Inflammation/Immunology Cancer
    Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .
    Rebamipide
  • HY-105507
    PF-10040

    		Platelet-activating Factor Receptor (PAFR) Inflammation/Immunology
    PF-10040 is a quinoline derivative that can inhibit PAF-induced airway hyperresponsiveness. PF-10040 also shows protective effect in experimental NSAID-gastritis .
    PF-10040
  • HY-162149
    Urease-IN-12

    		Bacterial Infection
    Urease-IN-12 (compound 5e) is a competitive urease inhibitor (IC50: 0.35 μM) with the potential to inhibit gastritis and peptic ulcer caused by Helicobacter pylori .
    Urease-IN-12
  • HY-162139
    Urease-IN-11

    		Bacterial Inflammation/Immunology
    Urease-IN-11 (Compound 6e) is a competitive urease inhibitor (IC50)=10.41 µM). Urease-IN-11 can be used to study diseases such as urease-related gastritis and peptic ulcer .
    Urease-IN-11
  • HY-163404
    Urease-IN-13

    		Bacterial Infection Inflammation/Immunology
    Urease-IN-13 (compound d8) is an inhibitor of urease with an IC50 value of 1.21 μM. Urease-IN-13 can be used in the study of infectious gastritis and gastric ulcer .
    Urease-IN-13
  • HY-B0758R
    Troxipide (Standard)

    		Calcium Channel Reference Standards Inflammation/Immunology
    Troxipide (Standard) is the analytical standard of Troxipide. This product is intended for research and analytical applications. Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties .
    Troxipide (Standard)
  • HY-B0360R
    Rebamipide (Standard)

    		COX Inflammation/Immunology Cancer
    Rebamipide (Standard) is the analytical standard of Rebamipide. This product is intended for research and analytical applications. Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .
    Rebamipide (Standard)
  • HY-B2206
    Gefarnate

    		Mucin Inflammation/Immunology
    Gefarnate is a agent used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome.
    Gefarnate
  • HY-B2191
    Sodium gualenate

    Guaiazulenesulfonate sodium

    		 Drug Derivative Inflammation/Immunology
    Sodium gualenate (Guaiazulenesulfonate sodium) is a hydrophilic derivative of guaiazulene with excellent anti-inflammatory and wound-healing effects mainly used for the treatment of duodenal ulcer, gastric ulcer and gastritis.
    Sodium gualenate
  • HY-B2191R
    Sodium gualenate (Standard)

    Guaiazulenesulfonate sodium (Standard)

    		 Drug Derivative Reference Standards Inflammation/Immunology
    Sodium gualenate (Standard) is the analytical standard of Sodium gualenate. This product is intended for research and analytical applications. Sodium gualenate (Guaiazulenesulfonate sodium) is a hydrophilic derivative of guaiazulene with excellent anti-inflammatory and wound-healing effects mainly used for the treatment of duodenal ulcer, gastric ulcer and gastritis.
    Sodium gualenate (Standard)
  • HY-122762
    Cetraxate hydrochloride

    DV-1006

    		 Ser/Thr Protease Inflammation/Immunology
    Cetraxate hydrochloride (DV-1006), an orally active anti-ulcer agent with mucosal protective effects, can be used for gastric ulcers research . Cetraxate hydrochloride is a potent acrosomal proteinase acrosin inhibitor with a Ki and an IC50 of 0.94 μM and 3.3 μM, respectively .
    Cetraxate hydrochloride
  • HY-N9451
    Ginger extract

    		NF-κB Cardiovascular Disease Inflammation/Immunology Cancer
    Ginger extract exhibits anti-cancer, anti-inflammatory and chemotherapeutic effects in vivo .
    Ginger extract

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: